Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 485.00
Bid: 480.00
Ask: 490.00
Change: -5.00 (-1.02%)
Spread: 10.00 (2.083%)
Open: 490.00
High: 490.00
Low: 485.00
Prev. Close: 490.00
SYS1 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

12 Apr 2007 07:01

BrainJuicer Group PLC12 April 2007 Press release 12 April 2007 BrainJuicer Group PLC ("BrainJuicer" or "the Company") Audited Preliminary Results for the Year ended 31 December 2006 Reported under IFRS BrainJuicer Group PLC (AIM: BJU), a leading international online market researchagency, announces its maiden audited preliminary results for the year ended 31December 2006. £'000 2003 2004 2005 2006 Before Listing Total Listing expenses expenses Revenue 1,032 2,614 2,936 4,608 4,608Operating Profit (304) 187 2 477 (354) 123Profit after Tax (301) 191 (38) 291 (354) (63) Highlights • Revenue increased by 57% to £4,608,000 (2005: £2,936,000) • Operating profit (before listing costs) increased to £477,000 (2005: £2,000) • Profit after tax (before listing costs) increased to £291,000 (2005: loss £38,000) • 172% revenue growth in the Netherlands in its second year of operation • Continued strong performance in the UK division • Awarded global mandate from one of the top 50 companies in the world • Established our business in the US • Strengthened our management team with appointment of a senior researcher from Research International to run the UK office and another from Millward Brown to run the US office • Rolled out 2 important new products: Predictive Markets and Quali-Taxi(TM) • Successful AIM IPO Commenting on the results, John Kearon, Chief Executive of BrainJuicer GroupPLC, said: "2006 was a very significant year for BrainJuicer. The Company nowhas 40 employees, strong relationships with approximately 80 clients, includingten of the world's top 50 companies, an innovative suite of products, a presencein three countries, a team of highly credible market research professionals, anda group of experienced software engineers. Our research platform, which wasdeveloped in-house, has won several respected industry awards and we are fastearning a reputation as an innovation leader in our industry. In our view, thiscombination would be very difficult to replicate and places us in a powerfulposition for sustainable growth within an attractive, rapidly growing market. "We have established a truly international footprint, adding the US to our Dutchand UK businesses and attracting two extremely talented and experiencedresearchers to run the US and UK offices. Our R&D unit, BrainJuicer Labs,introduced two highly innovative new products which contributed to our stronggrowth, accounting for 15% of turnover in their first year. Significantly in2006, we believe we became the first online research agency to win a globalmandate from a top 50 company and we ended the year with a successful listing onAIM." For further information, please contact: BrainJuicer Group PLC Tel: +44 (0)20 7043 1000 John Kearon, Chief Executive Officer john.kearon@brainjuicer.com James Geddes, Chief Financial Officer james.geddes@brainjuicer.com Teather & Greenwood Tel: +44 (0)20 7426 9000 James Maxwell / Fred Walsh / Simon Brown james.maxwell@teathers.com Media enquiries: Abchurch Communications Tel: +44 (0)20 7398 7700 Heather Salmond / Joanne Shears heather.salmond@abchurch-group.com Chairman's Statement Introduction 2006 has been a significant year in the life of the Company, includinggeographic expansion, considerable growth, and culminating in the successfulflotation on the AIM market of the London Stock Exchange in December 2006. The Company's financial performance has been strong and in line withexpectations. Turnover for the year increased by 57% to £4,608,000 (2005:£2,936,000). Operating profit rose from £2,000 in 2005 to £477,000 beforelisting expenses in 2006, and profit after taxation rose from a loss of £38,000to a profit of £291,000 before listing expenses, over the same period. Both of BrainJuicer's established business units, in the UK and Holland,performed well and the new unit in the US made a good start. Most of theCompany's revenue is transaction based, with 92% deriving from bespoke projectsand 8% deriving from Quali-Taxi(TM), our added-value version of what is termedan 'omnibus' in the industry i.e. simple, short, standard surveys. The Company generated £187,000 of cash from operations (before listing expenses)which together with the net proceeds from the flotation increased cash to£1,233,000. We have no borrowings. As this is BrainJuicer's first set of results as a public company, here is abrief summary of the Company's history. BrainJuicer was founded in 1999 with a conviction of the need to improve theinsightfulness and inspiration of quantitative research. This conviction wasbased on the firm belief that consumer focussed companies, the largest buyers ofmarket research, could make a step-change improvement in their innovationprocess if they had access to more profound consumer information than wasotherwise available. There was also a compelling argument that technology couldbe developed that used the internet to deliver research in a quicker, morecreative and ultimately more effective way than was previously possible. Over the first two years, the Company focussed on developing its methodology,conducting trials, and eventually winning BrainJuicer's first significant clientin 2002. In January 2003, Unilever Ventures invested £550,000 for an equitystake of approximately 40%, and we have since been steadily and patientlybuilding our team, client relationships and the software technology. With ourlisting on AIM, we have a mechanism to enable Unilever Ventures to exit overtime, and access to capital to pursue acquisition targets. Starting a business from scratch isn't always easy and is rarely plain sailing.We are a highly creative and innovative company. Despite being small, ourclients are some of the largest, and most demanding, buyers of market researchin the world and are hugely appreciative of our innovative research tools andhigh service ethic. Any company innovating in a market must be prepared forfailures and knock-backs along the way. This is something we have embraced fromthe beginning and it has proved a winning strategy. We intend to maintain ourbold approach to innovation and continue to delight our clients, in order toachieve our long term goal of becoming one of the top 10 global Market Researchagencies. Over the seven years of the Company's existence, we have created a suite ofinnovative research products, put in place an infrastructure and technologyplatform, and established a talented team of credible research professionals.In our view this combination would be very difficult to replicate, and places usin a powerful position for sustainable growth, within an attractive rapidlygrowing market. I am confident that we will continue to win in the market placeand that our client base will continue to grow. Geographic Expansion Following the success BrainJuicer has enjoyed in the Netherlands, the Boarddecided to take the important step of moving into the US. As well as being thesingle largest market, the US is also the most developed and competitive onlineresearch market in the world with 35% of all research now being conductedonline. Establishing a strong presence in the US is key to becoming a majorinternational research agency. As with the Company's move into the Netherlands,we entered the market in a low cost, low risk manner. First year losses were£66,000, which the Board views as a modest investment for what we now have: afour person high level account management team, and some significant newclients. The Board believes the business is now well placed to make significantin-roads in this coming year and is looking to continue the internationalexpansion in a similarly controlled and cost effective manner. BrainJuicer Labs As an innovation leader in the online market research industry, we areconstantly striving to create new ways to enable our clients to betterunderstand their consumers and to innovate more successfully. BrainJuicer Labsis our R&D capability made up of internal and external specialists that work ona project basis. In 2006 we rolled out Predictive Markets, a product which canhelp screen large numbers of concepts quickly, accurately and insightfully.Predictive Markets won a prestigious industry award for Best Methodology Paper,and accounted for 7% of turnover. We also introduced Quali-Taxi(TM), a highvalue-add "omnibus" product which without any promotional or advertising spend,accounted for 8% of turnover in its first year. Clients We were delighted with the way our client relationships have developed thisyear, and the jewel in the crown was the award of a global mandate from one ofthe top 50 companies in the world. We are mandated to test all of this client'sconsumer insights (a consumer insight is a precursor, in this particularcompany, to all product development). We feel that this is real tangibleevidence that we are beginning to become recognised as a genuine alternative tothe large incumbent agencies. Board of Directors Our Board comprises two executive directors, myself and James Geddes (our CFO),and two non-executive directors, Mark Muth and Simon Godfrey. James, Mark andSimon have each been with been with us since January 2003 and have contributedenormously to the success of the business in the intervening period. James Geddes is a Chartered Accountant originally at Touche Ross (now Deloitte)and prior to joining BrainJuicer was CFO of IoBox, an early stage company thatwas sold for €230m. He has a tremendous talent for understanding what it takesto turn start-ups into significant players. Mark Muth is one of three directors of Unilever Ventures, and has over 20 years'experience in banking and venture capital. Having been a director of many earlystage companies, Mark understands the highs and lows of the early years and hasbeen invaluable in helping us navigate the Company to its current position. Simon Godfrey has over 30 years' experience in quantitative research; he foundedand ran SGA, one of the largest UK research suppliers when acquired by WPP in1998. Simon's experience of delivering research to large clients makes him anextremely wise, knowledgeable and valuable member of the Board. The Board is well balanced, operates in an effective manner for a company of oursize, and takes its responsibilities to our shareholders seriously. Werecognise the need to split the roles of Chairman and CEO to further comply withbest practice, and are looking to appoint a non-executive Chairman later thisyear. Team Our management team comprises myself, James Geddes, and the Managing Directorsof our 3 businesses; the UK (Jim Rimmer), the Netherlands (Evert Bos) and the US(Ari Popper). I believe that BrainJuicer is now in the enviable position of possessing atalented and experienced team who are committed to building the Company into amajor international research house and a leader in online research. Evert Bos joined the team at the end of 2004 to manage the Dutch business.Evert was previously head of Market Research at Bestfoods, a subsidiary ofUnilever, in the Netherlands. Evert's 12 years of marketing and researchexperience have been invaluable in building a successful Dutch business. Jim Rimmer joined the team in June 2006 to manage the UK business. Jim has over20 years' research experience, previously as General Manager at SGA ResearchInternational. Already the UK research teams have benefited from Jim'sexceptional research talent and coaching ability to delight our clients andbuild our brand share and reputation. Ari Popper joined the team at the end of 2006 to manage the US business. Ariwas previously a Vice President at Millward Brown in the US and one of thesenior managers of their LA office. His nine years of marketing and researchexperience, extensive knowledge of the biggest customers in the US and desire tobuild a major new force in the US market made it a perfect fit on both sides. We have for a while felt that our creative techniques and innovative approach tomarket research creates a stimulating and creative work environment into whichwe can attract some of the most talented and experienced research professionalsfrom the large incumbents. So it was particularly gratifying to supplement ourteam with Jim and Ari during 2006. Our staff are loyal and dedicated and have coped remarkably well with thechallenges of working in a fast moving, high growth environment. I am verygrateful, and am committed to ensuring we continue to hire equally talentedstaff. Business and Financial Review Our Business We are a full service online market research agency. Our target marketcomprises consumer goods and services companies which are, in the main, thelargest buyers of market research in the world. We operate in Europe and the USwhich together form the geography from which the majority of the world'sresearch is purchased. Although BrainJuicer is not as large as somecompetitors, we compete head-on with the large traditional market researchproviders who dominate the market. We have a distinct, yet proven research approach, which is supported by ourproprietary software technology. The combination enables us to collect anddeliver quantitative data together with qualitative diagnostics quickly andefficiently. Our core products are firmly aimed at helping our clients throughout theirdevelopment process (be it development of products, packaging or advertising),particularly during the difficult 'fuzzy front end' of the typical innovationfunnel, when lots of ideas and concepts need to be tested in an insightful yetcost efficient way. Our projects tend to be bespoke and high in value, yet canbe delivered at low cost, relative to that of our competitors. We have conducted research in over 50 countries, in more than 30 languages, forover 80 clients (including 10 of the top 50 global companies). We have twooffices in the UK, and one in each of the Netherlands and the US. We own a panel of 33,000 respondents in the UK, but in the main accesspanellists from third party suppliers. Whilst we are a relatively young company, we have been recognised with thefollowing awards: • Best Methodology Paper (ESOMAR); • Most Innovative Use of IT (Effective IT Awards); and • Service Business of the Year (Start-up Awards). Our Objectives We have three simple operational imperatives: • to deepen our client relationships by continuing to exceed expectations in each and every project we undertake; • to continue to create new online research techniques, which enable our clients to engage with their consumers more intimately and more immediately; and • to continue to improve the sophistication of our technology and the quality of our internal processes. We believe that this combination will enable: • higher average revenue, and therefore profit, per project; • significant growth from our existing client base; and • increased capacity from our operations; which together will result in growth which is both highly profitable andsustainable. We also believe that this will provide a stimulating work environment into whichwe can continue to attract, and retain, high calibre market researchprofessionals and software engineers. Having successfully established our business in the Netherlands and the US, wewill be looking to expand our geographic footprint in Europe and to follow ourclients into China. Our overseas offices use our central UK infrastructure toservice their operational, financial and administrative needs, so providing wecan find the right people, we can open overseas offices cheaply and quickly. Our Operations We were pleased with the strong performance of each of our three accountmanagement teams. Gross profit, our primary top-line performance metric, grewin the UK by 20% and in Holland by 143%, which together with a first year grossprofit of £278,000 in the US, resulted in overall gross profit growth of 50%.We achieved this growth with only a small increase in overall headcount, from anaverage of 34 in 2005 to 38 in 2006. New Products BrainJuicer Labs continued to innovate, and we rolled out two new products in2006: Predictive Markets and Quali-Taxi(TM). Our new products start life asexperimental projects, then are written up as research papers, extensivelytrialled with client partners and finally, are launched. Predictive Markets. The basic premise behind Predictive Markets is thecounter-intuitive proposition that in a properly controlled environment, crowdscan make better decisions than experts. We have tested, and have found that acrowd of non-experts, when operating through a market mechanism, can be just asaccurate as established research approaches. Using this insight, PredictiveMarkets, is able to test a multitude of concepts and ideas accurately and atvery much lower cost than traditional techniques. In 2005, this won an ESOMARaward for Best Methodology Paper, and after further trials was launched duringQ2 of 2006. It accounted for 7% of turnover in its first year. Quali-Taxi(TM). A Quali-Taxi(TM) is our version of an omnibus (a survey in whichquestions from many organisations are compiled and presented to a nationallyrepresentative sample of the population at certain predetermined times, anddelivered a few weeks later). However, unlike an omnibus, a Quali-Taxi(TM) givesa client its own tailored survey which starts whenever the client wants, withonly that client's questions, and includes our qualitative, as well as thestandard quantitative, question types. In its first year, Quali-Taxi(TM)'sgenerated £366,000 in revenue, without any significant up-front investment, orany advertising or other promotional spend. Clients Our top 20 clients, representing 75% of our revenue, are all large well-knownconsumer focussed companies. In the main we have developed our relationshipswith these key accounts well. 70% grew substantially in 2006, 10% were new tous, and only 20% declined. We were particularly pleased to be entrusted with aglobal mandate from one of our largest clients, for all of their Insighttesting. This has led to a step-change improvement in our relationship withthis client. It is also pleasing that most of our clients use BrainJuicer on an on-goingbasis; 85% of our 2006 revenue was from repeat business, and 15% from newclients won during the year. Average spend per project increased from £11,468in 2005 to £13,317 in 2006. Our Financials Operating Profit Our revenue growth drove up operating profit from what was essentiallybreak-even in 2005 (£2,000) to £477,000 before listing costs. Our keyproductivity and efficiency metric, gross margin per hour, increased to £171 perhour (2005: £165 per hour). Administrative expenses increased 29% from £2,284,000 to £2,942,000 (excludinglisting expenses of £354,000). £343,000 of this relates to employee costs andoverheads in our US office which opened in late 2005. In addition, we paid abonus of £291,000 (zero in 2005). We have a scalable business model and can continue to grow with only modestincreases in the headcount of our management, administrative and technical teams(approximately half of our headcount). Taxation Our effective tax rate in 2006 before disallowable listing expenses was 35.1%(2005: nil). This is above the standard rate of taxation of 30% in the UKprincipally due to certain legal fees and preference share interest chargesbeing disallowable for corporation tax purposes, and US tax losses for which wehave taken no credit this year. We anticipate the effective rate of tax willdecline in future years. Cash flow In listing on AIM, we issued 1,388,900 new ordinary shares at £1.08, raisingproceeds of £1,500,000. We incurred listing expenses of £455,000 of which£354,000 was charged to the income statement and £101,000 offset against sharepremium. The net proceeds were £1,045,000. We generated cash from operations before listing expenses of £187,000 (2005:£207,000 outflow). This is especially pleasing given the early stage nature ofour Dutch business and investment in establishing our US business. Balance sheet We have low levels of capital expenditure - £92,000 this year in improving ourUK offices and in some IT equipment. Non-current assets also include a deferred tax asset of £213,000 which relatesto the future corporate tax deductions available to the Group when share optionholders exercise their share options. Of this amount, £207,000 has beencredited directly to equity, as required by International Financial ReportingStandards ("IFRS"). Trade receivables (including accrued income) have grown from £788,000 to£1,612,000. Debtor days have grown from 74 to 88 but remain in control, and wehad no bad debts. Trade and other payables have increased from £409,000 to £944,000 principallydue to year end bonus accruals. Financial liabilities relate to dividends due to preference shareholders, whichaccrued until they were converted to ordinary shares. We anticipate havingsufficient distributable reserves to pay these dividends during 2007. International Financial Reporting Standards ("IFRS") We have prepared our Annual Report under IFRS. The main difference between UKGAAP and IFRS impacting BrainJuicer is: • Credit to equity of £207,000 relating to the recognition of a deferred tax asset of £213,000 for the future anticipated tax deduction relating to our stock option charge. We have also included a charge for stock options in accordance with IFRS 2 "Share-based payment" of £22,000 (2005: £26,000) (this would also have been a UKGAAP requirement this year). A full list of our accounting policies under IFRS can be found in note 2 of thispreliminary announcement. Prospects We believe our market positioning, our client relationships and our low costscaleable business model set us up for sustainable, highly profitable growth. John KearonChief Executive Officer12 April 2007 CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2006 2006 2005 Note £'000 £'000ASSETSNon-current assetsProperty, plant and equipment 78 -Deferred tax asset 213 - 291 - Current assetsInventories 45 13Trade and other receivables 1,612 788Cash and cash equivalents 1,233 64 2,890 865 Total assets 3,181 865 EQUITYCapital and reserves attributable to equity holders of theCompanyShare capital 126 111Share premium account 1,390 -Merger reserve 477 445Foreign currency translation reserve (5) 1Other reserve 255 26Retained earnings (277) (214) Total equity 1,966 369 LIABILITIESCurrent liabilitiesTrade and other payables 944 408Current income tax liabilities 163 -Financial liabilities 108 - 1,215 408Non-current liabilitiesFinancial liabilities - 88 Total liabilities 1,215 496 Total equity and liabilities 3,181 865 CONSOLIDATED INCOME STATEMENT FOR YEAR ENDED 31 DECEMBER 2006 Note 2006 2006 2006 2005 Before Listing Listing expenses expenses Total £'000 £'000 £'000 £'000 Revenue 3 4,608 - 4,608 2,936Cost of sales (1,189) - (1,189) (650) Gross profit 3,419 - 3,419 2,286Administrative expenses (2,942) (354) (3,296) (2,284) Operating profit 477 (354) 123 2Investment income 3 - 3 4Finance costs (32) - (32) (44) Profit / (loss) before taxation 448 (354) 94 (38)Income tax expense (157) - (157) - Profit / (loss) for the financial year 291 (354) (63) (38) Attributable to equity holders of theCompany (63) (38) Earnings per share attributableto the equity holders of the CompanyBasic loss per share 4 (0.9p) (0.6p) Diluted loss per share 4 (0.9p) (0.6p) All of the activities of the group are classed as continuing. CONSOLIDATED CASH FLOW STATEMENT FOR YEAR ENDED 31 DECEMBER 2006 2006 2005 Note £'000 £'000 Net cash used by operations 5 (167) (207)Interest paid (1) - Net cash used by operating activities (168) (207) Cash flows from investing activitiesPurchases of property, plant and equipment (92) -Interest received 3 4 Net cash (used by)/generated from investing activities (89) 4Cash flows from financing activitiesProceeds from initial public offering net of share issue expenses 1,399 -Proceeds from other issue of ordinary shares 27 - Net cash generated from financing activities 1,426 - Net increase/(decrease) in cash and cash equivalents 1,169 (203) Cash and cash equivalents at beginning of year 64 267 Cash and cash equivalents at end of year 1,233 64 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY AS AT 31 DECEMBER 2006 Share Share Merger Foreign Other Retained Total capital premium reserve currency reserve earnings account translation reserve £'000 £'000 £'000 £'000 £'000 £'000 £'000 At 1 January 2005 111 - 445 - - (176) 380 Exchange differences on -consolidation - - 1 - - 1Loss for the financial year - - - - - (38) (38) Total income / (expense)recognised for 2005 - - - 1 - (38) (37)Share-based payment charge - - - - 26 - 26 - - - 1 26 (38) (11) At 31 December 2005 111 - 445 1 26 (214) 369 Exchange differences onconsolidation - - - (6) - - (6)Deferred tax credited toequity - - - 207 - 207Loss for the financial year - - - - - (63) (63) Total income / (expense) recognised for 2006 - - - (6) 207 (63) 138Shares issued prior toGroup reconstruction - - 21 - - - 21Transfer of liabilityelement of preferred sharesto equity - - 11 - - - 11Shares issued on IPO 14 1,486 - - - - 1,500Share issue costs deducted from equity - (101) - - - - (101)Share options exercisedsubsequent to Groupreconstruction 1 5 - - - - 6Share-based payment charge - - - - 22 - 22 15 1,390 32 (6) 229 (63) 1,597At 31 December 2006 126 1,390 477 (5) 255 (277) 1,966 1. Basis of Preparation The financial information set out above in respect of 31 December 2006 does notconstitute statutory accounts as defined in section 240 of the Companies Act.The financial information contained in this announcement has been extracted fromthe 2006 financial statements upon which the auditors' opinion is unqualifiedand does not include any statement under Section 237 of the Companies Act 1985. Whilst not yet an AiM requirement, the Group has chosen to prepare its maidenpreliminary announcement in accordance with International Financial ReportingStandards ("IFRSs") as adopted in the European Union and as applied inaccordance with the provisions of the Companies Act 1985. The disclosuresrequired by IFRS 1, First-time Adoption of International Financial ReportingStandards, in respect of the transition from accounting principles generallyaccepted in the United Kingdom ("UK GAAP") to IFRS are provided in note 6. The preliminary announcement has been prepared under the historical costconvention. First time adoption of IFRS As permitted by IFRS 1, the following key exemptions have been taken in thetransition to IFRS. Recognition and measurement requirements of IFRS 2 'ShareBased Payments' have only been applied to equity instruments granted after 7November 2002 that had not vested by 1 January 2005. Cumulative translationdifferences for all foreign currency operations have been reset to nil as at 1January 2005. 2. Principal accounting policies The principal accounting policies applied in the preparation of theseconsolidated results are set out below. These policies have been consistentlyapplied to all the years presented, unless otherwise stated. Basis of consolidation On 14 November 2006, the Company acquired, in return for the issue of new equityshare capital, the entire issued share capital of BrainJuicer Limited. As theshareholders were identical before and after this transaction, this share forshare exchange qualifies as a common control transaction and a groupreorganisation and falls outside of the scope of IFRS 3, Business Combinations. Consequently, merger accounting has been adopted. No goodwill has beenrecorded and the difference between the parent Company's cost of investment andBrainJuicer Limited's share capital and share premium is presented as a mergerreserve within equity on consolidation. Comparative amounts are restated as ifthe combination had taken place at the beginning of the earliest comparativeperiod presented. Accordingly, the Group financial statements have beenprepared as if the Group was in existence for the whole of the current and prioryears. The consolidated financial statements incorporate the financial statements ofthe Company and all entities controlled by it after eliminating internaltransactions. Control is achieved where the Group has the power to govern thefinancial and operating policies of a Group undertaking so as to obtain economicbenefits from its activities. Undertakings' results are adjusted, whereappropriate, to conform to group accounting policies. Property, plant and equipment Property, plant and equipment is stated at historical cost less accumulateddepreciation. Depreciation is provided to write off the cost of all property,plant and equipment to its residual value on a straight-line basis over itsexpected useful economic lives, which are as follows: Leasehold improvements 5 years or over the period of the lease, if shorterFurniture, fittings and equipment 5 yearsComputer hardware 2 to 3 years Impairment of property, plant and equipment At each balance sheet date, the Group reviews the carrying amounts of itsproperty, plant and equipment for any indication that those assets have sufferedan impairment loss. If any such indication exists, the recoverable amount ofthe asset is estimated in order to determine the extent of the impairment loss,if any. The recoverable amount is the higher of the fair value less costs tosell and value in use. Cash and cash equivalents Cash and cash equivalents comprise cash in hand and bank deposits available ondemand. Trade receivables Trade receivables are stated at fair value, taking into account estimatedirrecoverable amounts which are recognised where there is evidence that the fullamount of the trade receivable is not collectible, and are charged to the incomestatement. Inventories - work in progress Work in progress comprises directly attributable costs on incomplete marketresearch projects and is held in the balance sheet at the lower of cost and netrealisable value. Trade payables Trade payables are stated at fair value and are not interest bearing. Fairvalue normally equates to the amount payable due to their short term nature. Income taxes Current income tax liabilities comprise those obligations to fiscal authoritiesrelating to the current or prior reporting period, that are unpaid at thebalance sheet date. They are calculated according to the tax rates and tax lawsapplicable to the fiscal periods to which they relate, based on the taxableprofit for the year. All changes to current tax assets or liabilities arerecognised as a component of tax expense in the income statement, except whereit relates to items charged or credited directly to equity. Deferred income taxes are calculated using the liability method on temporarydifferences. This involves the comparison of the carrying amounts of assets andliabilities in the consolidated financial statements with their respective taxbases. In addition, tax losses available to be carried forward as well as otherincome tax credits to the Group are assessed for recognition as deferred taxassets. Deferred tax liabilities are always provided for in full. Deferred tax assetsare recognised to the extent that it is probable that the underlying deductibletemporary differences will be able to be offset against future taxable income.Deferred tax assets and liabilities are calculated, without discounting, at taxrates that are expected to apply to their respective period of realisation,provided they are enacted or substantively enacted at the balance sheet date. Deferred tax is recognised as a component of tax expense in the incomestatement, except where it relates to items charged or credited directly toequity. Operating lease agreements Rentals applicable to operating leases where substantially all of the benefitsand risks of ownership remain with the lessor are charged to the incomestatement net of any incentives received from the lessor on a straight linebasis over the period of the lease. Revenue recognition Revenue is recognised when the right to consideration has been obtained for eachmarket research project, which is normally after delivery of the project debriefto the client. Delivery of the debrief is the most significant act of eachproject. Employee benefits All accumulating employee-compensated absences that are unused at the balancesheet date are recognised as a liability. Share-based payment transactions The Group issues equity settled share-based compensation to certain employees(including directors). Equity settled share-based payments are measured at fairvalue at the date of grant. The fair value determined at the grant date of theequity-settled share-based payment is expensed on a straight-line basis over thevesting period, together with a corresponding increase in equity, based upon theGroup's estimate of the shares that will eventually vest. These estimates aresubsequently revised if there is any indication that the number of optionsexpected to vest differs from previous estimates. Any cumulative adjustmentprior to vesting is recognised in the current period. No adjustment is made toany expense recognised in prior periods. Fair value is measured by an external valuer using the Black-Scholes pricingmodel. The expected life used in the model has been adjusted, based onmanagement's best estimate, for the effects of non-transferability, exerciserestrictions and behavioural considerations. Where the terms of an equity-settled transaction are modified, as a minimum anexpense is recognised as if the terms had not been modified. In addition, anexpense is recognised for any increase in the value of the transaction as aresult of the modification, as measured by the date of modification. Where an equity-settled transaction is cancelled, it is treated as if it hadvested on the due date of the cancellation, and any expense not yet recognisedfor the transaction is recognised immediately. However, if a new transaction issubstituted for the cancelled transaction, and designated as a replacementtransaction on the date that it is granted, the cancelled and new transactionsare treated as if they were a modification of the original transaction, asdescribed in the previous paragraph. Foreign currencies Monetary assets and liabilities in foreign currencies are translated intosterling at the rates of exchange prevailing at the balance sheet date.Transactions in foreign currencies are translated into sterling at the rate ofexchange prevailing at the date of the transaction. Exchange gains and lossesare included in the income statement for the period. For consolidation purposes, the trading results and cash flows in foreigncurrencies, arising in foreign subsidiaries, are translated into sterling ataverage exchange rates for the period. Assets and liabilities denominated inforeign currencies are translated using the rate of exchange prevailing at thebalance sheet date. Exchange differences arising upon consolidation are takendirectly to the cumulative foreign currency translation reserve. Suchtranslation differences are recognised as income or expense in the period inwhich the operation is disposed of. Segment reporting A segment is a distinguishable component of the group that is engaged inproviding products or services within a particular economic environment(geographical segment). Financial instruments/ liabilities Financial liabilities and equity instruments are classified according to thesubstance of the contractual arrangements entered into. An equity instrument isany contract that evidences a residual interest in the assets of the entityafter deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including sharecapital) are equivalent to a similar debt instrument, those financialinstruments are classed as financial liabilities. Financial liabilities arepresented as such in the balance sheet. Finance costs and gains or lossesrelating to financial liabilities are included in the income statement. Financecosts are calculated so as to produce a constant rate of return on theoutstanding liability. Where the contractual terms of share capital do not have any terms meeting thedefinition of a financial liability then this is classed as an equityinstrument. Dividends and distributions relating to equity instruments aredebited direct to equity. Compound instruments Compound instruments comprise both a liability and an equity component. At dateof issue, the fair value of the liability component is estimated using theprevailing market interest rate for a similar debt instrument. The liabilitycomponent is accounted for as a financial liability. The residual is the difference between the net proceeds of issue and theliability component (at time of issue). The residual is the equity component,which is accounted for as an equity instrument. The interest expense on the liability component is calculated applying theeffective interest rate for the liability component of the instrument. Thedifference between this amount and any repayments is added to the carryingamount of the liability in the balance sheet. Share capital Ordinary shares are classified as equity. Equity instruments issued by theCompany are recorded at the proceeds received, net of direct issue costs. Share premium Share premium represents the excess over nominal value of the fair value ofconsideration received for equity shares, net of expenses of the share issue. Other reserve The other reserve represents equity-settled share-based employee remunerationuntil such share options are exercised and deferred tax taken directly to equityin respect of such options. Merger reserve The merger reserve represents the difference between the parent company's costof investment and a subsidiary's share capital and share premium where abusiness combination qualifies as a common control transaction. Foreign currency translation reserve The foreign currency translation reserve represents the differences arising fromtranslation of investments in overseas subsidiaries. 3. Segment information The Group operates in one business segment, that of market research. Whilstthere are a number of products within the business segment, management reportingis principally based on location of service delivery. Accordingly the Grouppresents its primary segment analysis on this basis: Year ended 31 December 2006 United Europe Rest of the Group Total Kingdom World £'000 £'000 £'000 £'000 £'000 Total segment revenue 3,065 1,198 375 - 4,638Inter segment revenue (30) - - - (30) Segment revenue 3,035 1,198 375 - 4,608 Segment result 860 529 (66) (1,200) 123 Investment income 3Finance costs (32) Profit before taxation 94 Taxation (157) Loss for the financial year (63) Segment assets 1,072 855 237 1,264 3,428 Segment liabilities (712) (179) (300) (271) (1,462) Net assets 360 676 (63) 993 1,966 Capital expenditure 86 3 3 - 92 Depreciation 13 1 - - 14 Group costs include directors' remuneration and central project costs which arenot directly attributable to geographic segments. Group assets include centrally held cash at bank and deferred tax assets. Groupliabilities include income tax and financial liabilities. Year ended 31 December 2005 United Europe Rest of the Group Total Kingdom World £'000 £'000 £'000 £'000 £'000 Total segment revenue 2,533 440 - - 2,973Inter segment revenue (23) (14) - - (37) Segment revenue 2,510 426 - - 2,936 Segment result 891 142 - (1,031) 2 Investment income 4Finance costs (44) Loss before taxation (38) Taxation - Loss for the financial year (38) Segment assets 631 234 - - 865 Segment liabilities (331) (77) - (88) (496) Net assets 300 157 - (88) 369 Capital expenditure - - - - - Depreciation - - - - - Group costs include directors' remuneration and central project costs which arenot directly attributable to geographic segments. Group liabilities include income tax and financial liabilities. 4. Earnings per share (a) Basic Basic earnings per share is calculated by dividing the profit attributable toequity holders of the Company by the weighted average of ordinary shares inissue during the year. 2006 2005 £'000 £'000 Loss attributable to equity holders of the Company (63) (38)Listing expenses 354 - Adjusted profit/(loss) before listing expenses attributable to equity holders of 291 (38)the Company Weighted average number of ordinary shares in issue 7,196,792 6,126,465 Basic loss per share (0.9p) (0.6p) Adjusted basic earnings/(loss) per share before listing expenses 4.0p (0.6p) (b) Diluted Diluted earnings per share is calculated by adjusting the weighted averagenumber of shares outstanding to assume conversion of all dilutive potentialordinary shares. For share options, a calculation is made in order to determinethe number of shares that could have been acquired at fair value (determined asthe average annual market share price of the Company's shares) based on themonetary value of the subscription rights attached to outstanding share options. The number of shares calculated in this way is compared with the number ofshares that would have been issued assuming the exercise of the share options. 2006 2005 £'000 £'000 Loss attributable to equity holders of the Company (63) (38)Interest expense on convertible preference shares 31 43 (Loss) / profit used to determine diluted earnings per share (32) 5 Listing expenses 354 - Adjusted profit used to determine adjusted diluted earnings per share 322 5 Weighted average number of ordinary shares in issue 7,196,792 6,126,465Assumed conversion of convertible preference shares 4,014,201 4,817,041Share options 364,377 312,209 Weighted average number of ordinary shares for diluted earnings per share 11,575,370 11,255,715 Diluted loss per share (0.9p) (0.6p) Adjusted diluted earnings/(loss) per share before listing expenses 2.8p (0.6p) The share options and convertible preference shares are considered to beanti-dilutive in 2005 and anti-dilutive after listing expenses in 2006. 5. Cash used by operations 2006 2005 £'000 £'000 Profit /(loss) before taxation 94 (38)Depreciation 14 -Net finance costs 29 40Share-based payment expense 22 26Increase in inventory (32) (5)Increase in receivables (824) (222)Increase/(decrease) in payables 536 (9)Exchange differences (6) 1 Net cash used by operations (167) (207) 6. First time adoption of IFRS Key impact analysis The analysis below sets out the most significant adjustments arising from thetransition to IFRS. 1) Presentation of financial statements The format of the Group's primary financial statements has been presented inaccordance with IAS 1 "Presentation of Financial Statements". 2) Share-based payment IFRS 2, "Share based payment" requires that an expense for equity settled sharebased payment be recognised in the financial statements based on their fairvalue at the date of grant. This expense, which is in relation to employeeshare options granted under an EMI scheme, is recognised over the vesting periodof the options. IFRS 2 has been applied to all options granted after 7 November 2002 and notfully vested by 1 January 2005, the Group's date of transition to IFRS. 3) IAS 19 Employee benefits Under IAS 19, all accumulating employee-compensated absences that are unused atthe balance sheet date must be recognised as a liability. There is no similarrequirement under UK GAAP. In addition, employee benefits which fall within thescope of IAS 19 have been recognised in the Group's balance sheet. 4) Foreign exchange differences Under IAS 21 "The effects of changes in foreign exchange rates", exchangedifferences arising upon consolidation are taken directly to a cumulativetranslation reserve rather than to the profit and loss account. Suchtranslation differences are recognised as income or expense in the period inwhich the operation is disposed of. Differences between UK GAAP applicable at 1 January 2005 and UK GAAP at the dateof this report reflect the implementation of the following standards: • Financial Reporting Standard No. 20 'Share-based payments'; and • Financial Reporting Standard No. 26 'Financial Instruments: Measurement' Reconciliation of equity as at 1 January 2005 (date of transition to IFRS) UK GAAP Employee IFRS benefits £'000 £'000 £'000ASSETS Non-current assetsProperty, plant and equipment - - -Deferred tax asset - - - - - -Current assetsInventories 8 - 8Trade and other receivables 566 - 566Cash and cash equivalents 267 - 267 Total assets 841 - 841 EQUITYShare capital 111 - 111Share premium account 445 - 445Other reserves - - -Retained earnings (166) (10) (176) Total equity 390 (10) 380 LIABILITIESCurrent liabilitiesTrade and other payables 355 10 365Current income tax liabilities 53 - 53 408 10 418Non-current liabilitiesFinancial liabilities 43 - 43 Total liabilities 451 10 461 Total equity and liabilities 841 - 841 Reconciliation of income statement for the year ended 31 December 2005 UK GAAP Share-based Employee IFRS payment benefits £'000 £'000 £'000 £'000 Revenue 2,936 - - 2,936Cost of sales (650) - - (650) Gross profit 2,286 - - 2,286Administrative expenses (2,253) (26) (5) (2,284) Operating profit 33 (26) (5) 2Investment income 4 - - 4Finance costs (44) - - (44) Loss before taxation (7) (26) (5) (38)Income tax expense - - - - Loss for the financial year (7) (26) (5) (38) Reconciliation of equity as at 31 December 2005 UK GAAP Share-based Employee Foreign IFRS payment benefits exchange £'000 £'000 £'000 £'000 £'000ASSETSNon-current assetsTangible fixed assets - - - - -Deferred tax asset - - - - - - - - - - Current assetsInventories 13 - - - 13Trade and other receivables 788 - - - 788Cash and cash equivalents 64 - - - 64 865 - - - 865 EQUITYShare capital 111 - - - 111Merger reserve 445 - - - 445Foreign currency translation reserve - - - 1 1Other reserve - 26 - - 26Retained earnings (172) (26) (15) (1) (214) Total equity 384 - (15) - 369 LIABILITIESCurrent liabilitiesTrade and other payables 393 - 15 - 408Current income tax liabilities - - - - - 393 15 408 Non-current liabilitiesFinancial liabilities 88 - - - 88 Total liabilities 481 15 496 Total equity and liabilities 865 - - - 865 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th Apr 20247:00 amRNSTrading Update
24th Jan 20247:00 amRNSTrading Update
12th Dec 202312:51 pmRNSPresentation via Investor Meet Company
6th Dec 20237:00 amRNSChange of Auditor
6th Dec 20237:00 amRNSInterim Results
24th Oct 20237:00 amRNSTrading Update
27th Sep 20236:00 pmRNSResult of AGM
27th Sep 20237:00 amRNSTrading Update
31st Aug 20237:00 amRNSAnnual Report and Notice of AGM
1st Aug 20237:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2023
31st Jul 20232:00 pmRNSPreliminary Results Presentation
13th Jul 20237:30 amRNSTrading update
30th Jun 20239:00 amRNSResolution of Complaint for Trademark Infringement
28th Jun 202311:00 amRNSHolding(s) in Company
3rd May 20233:15 pmRNSFurther re Result of General Meeting
21st Apr 202311:56 amRNSResult of General Meeting
13th Apr 20237:00 amRNSFurther re Requisitioned General Meeting
12th Apr 20237:00 amRNSTrading Update
5th Apr 202310:45 amRNSNotice of Trading Update
24th Mar 20234:00 pmRNSPosting of Circular and Notice of Requisitioned GM
24th Mar 20237:00 amRNSPosting of Circular and Notice of Requisitioned GM
7th Mar 20237:30 amRNSReceipt of Requisition Notice
28th Feb 202312:50 pmRNSCapital Markets Day
23rd Feb 20237:00 amRNSTrading Update
14th Feb 20237:00 amRNSCapital Markets Day
13th Jan 20232:00 pmRNSDirector/PDMR Shareholding
10th Jan 202310:30 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 20224:00 pmRNSDirector/PDMR Shareholding
13th Dec 20226:25 pmRNSDirector/PDMR Shareholding
6th Dec 20224:15 pmRNSDirectorate Change
30th Nov 20227:00 amRNSInterim Results
25th Oct 20227:00 amRNSTrading Update
28th Sep 20226:15 pmRNSResult of AGM
31st Aug 202211:00 amRNSNotice of AGM
31st Aug 20227:00 amRNSDirectorate Change
31st Aug 20227:00 amRNSReview of strategic options
30th Aug 20226:00 pmRNSTransaction in Own Shares
19th Aug 20228:55 amRNSTransaction in Own Shares
3rd Aug 20225:45 pmRNSTransaction in Own Shares
2nd Aug 20223:45 pmRNSTransaction in Own Shares
29th Jul 20229:30 amRNSTransaction in Own Shares
26th Jul 20226:24 pmRNSTransaction in Own Shares
19th Jul 20224:00 pmRNSHolding(s) in Company
19th Jul 20223:00 pmRNSTransaction in Own Shares
18th Jul 20224:30 pmRNSTransaction in Own Shares
15th Jul 20225:15 pmRNSTransaction in Own Shares
12th Jul 20227:00 amRNSShare Buyback Programme
12th Jul 20227:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2022
12th Jul 20227:00 amRNSQuarterly Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.